Summary
In an open, randomized, comparative, between-patient trial, 45 postmenopausal women were treated for 4 months with cyclical transdermal oestradiol 0.05 mg per day or oral conjugated equine oestrogens 0.625 mg per day, in both cases, plus, medroxyprogesterone acetate 10 mg per day on the last 8 days of each cycle. Similar relief from postmenopausal symptoms was obtained with both treatments. Post-treatment histological evaluation of the endometrium did not reveal neoplastic or hyperplastic change in any patient.
Early follicular-phase plasma oestradiol levels were observed only after transdermal oestradiol. There was a significant reduction in serum total cholesterol and LDL cholesterol in both treatment groups, with no difference between treatments, whereas serum triglyceride levels were decreased only by transdermal oestradiol. Plasma calcium and phosphorus fell significantly and serum intact parathyroid hormone rose significantly, with no difference between the therapies. No significant changes were observed in clotting factors.
Transdermal oestradiol appears to be an effective and safe hormonal replacement therapy, and this route of administration may be responsible for the more useful action of the drug on serum lipids and plasma oestradiol levels.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hammond CB, Maxson WS (1986) Estrogen replacement therapy. Clin Obstet Gynecol 29: 407–430
Jick H, Dinan B, Rothman KH (1978) Non contraceptive estrogens and nonfatal myocardial infarction. JAMA 239: 1407–1408
Stern MP, Brown BW, Haskel WL, Farquhar TW, Where-lead CL, Woods PDS (1976) Cardiovascular risk and use of estrogens or estrogen-progestagen combinations. JAMA 235: 811–815
Ziel HK, Finkle WD (1975) Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293: 1167–1170
Smith DC, Brentice R, Thrompson DJ, Herrman WL (1975) Association of exogenous estrogen and endometrial cancer. N Engl J Med 293: 1164–1167
Jick H, Watkins RN, Hunter JR et al. (1979) Replacement estrogens and endometrial cancer. N Engl J Med 300: 218–222
Hoover R, Gray LA, Cole P, Macmahon B (1976) Menopausal estrogens and breast cancer. N Engl J Med 295: 401–405
Powers MS, Schenkel L, Darley PE, Good WR, Balestra GC, Place VA (1985) Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta estradiol: Comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 152: 1099–1106
Schenkel L, Balestra J, Schmitt L, Schaw J (1985) Transdermal estrogen substitution in the menopause. Rate control in drug therapy. LF Prescott and WS Nimmo — Proc. Second Edinburgh Internat. Conf. on Drug Absorption. 1983. Livingstone, Edinburgh, 294–303
Laufer LR, Defazio GL, Lu JK et al (1983) Estrogen replacement therapy by transdermal estradiol administration. Am J Obstet Gynecol 146: 533–540
Padwick ML, Endacott J, Whitehead MI (1985) Efficacy, acceptability, and metabolic effects of transdermal estradiol in the management of postmenopausal women. Am J Obstet Gynecol 152: 1085–1091
Chetkowski RJ, Meldrum DR, Steingold KA et al (1986) Biologic effects of transdermal estradiol. N Engl J Med 314: 1615–1620
Whitehead MI, Padwick ML, Endacott J, Pryse-Davies J (1985) Endometrial responses to transdermal estradiol in postmenopausal women. Am J Obstet Gynecol 152: 1079–1084
Kupperman HS, Wetchler BB (1959) Contemporary therapy of the menopausal syndrome. JAMA 171: 1627–1637
Steingold KA, Laufer L, Chetkowski RJ et al. (1985) Treatment of hot flushes with transdermal estradiol administration. J Clin Endocrinol Metab 61: 627–632
Christiansen C, Christiansen MS, McNair P, Hagen C, Stocklund KE, Transbol I (1980) Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 10: 273–279
Riis BJ, Thomsen K, Strom V, Christiansen C (1987) The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 156: 61–65
Lindsay R (1982) The role of sex hormones and synthetic steroids in prevention of postmenopausal osteoporosis. Clin Invest Med 5: 189–194
Eriksen EF, Colvard DS, Berg NJ et al. (1988) Evidence of estrogen receptor in normal human osteoblast-like cells. Science 241: 84–86
Stevenson JC, Abeyasekera G, Hillyard CJ et al. (1981) Calcitonin and the calcium-regulating hormones in postmenopausal women: effect of oestrogens. Lancet I: 693–695
Gallagher JC, Riggs L, De Luca HF (1980) Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis. J Clin Endocrinol Metab 51: 1359–1364
Greenberg C, Kukreja SC, Bowsre EN et al. (1987) Effect of estradiol and progesterone. Metabolism 36: 151–154
Duarte B, Hargis KG, Kukreja SC (1988) Effects of estradiol and progesterone on parathyroid hormone secretion from human parathyroid tissue. J Clin Endocrinol Metab 66: 584–587
Johansen JR, Riis PJ, Pødenphant J, Skakkeboek NE, Christiansen C (1987) Plasma bone Gla-protain: a specific marker of bone formation. In: Christiansen C, Johansen JR, Riis PJ; Osteoporosis, Osteopress Aps Copenhagen, pp. 677–681
Wallace RB, Hoover J, Barrett-Conner E et al. (1979) Altered plasma lipids and lipoprotein levels associated with oral contraceptive and estrogen use. Lancet II: 111–114
Jensen J, Riis BJ, Strom V, Nilas L, Christiansen C (1987) Long term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 156: 66–71
De Lignieres B, Basdevant A, Thomas G et al. (1986) Biological effects of estradiol 17-beta in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 62: 536–541
Elkik F, Gompel A, Mercier-Bodard C et al. (1982) Effects of percutaneous estradiol and conjugated estrogens on the level of plasma proteins and triglycerides in postmenopausal women. Am J Obstet Gynecol 143: 888–892
Conrad J, Cazenave B, Samama M, Harellon MH (1980) AtIII content and antithrombin activity in oestrogen-progestogen and progestogen only treated women. Thromb Res 18: 675–683
Meade TW, Mellons S, Brozovic M et al. (1986) Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet ii: 533–537
Stone MC, Thorpe JM (1985) Plasma fibrinogen — a major coronary risk factor. J R Coll Gen Pract 35: 565–569
Kannel WB, Wolf PA, Castelli WP, D'Agostino RB (1987) Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA: 258: 1183–1186
Meade TW, Greenberg G, Thompson SG (1980) Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50 and 30 mcg oestrogen preparations. Br Med J 280: 1157–1161
Astedt B (1971) Low fibrinolytic activity of vein during treatment with ethinyloestradiol. Acta Obstet Gynecol Scand 50: 279–283
Jespersen J, Kluft C (1986) Inhibition of tissue-type plasminogen activator in plasma of women using oral contraceptives and in normal women during a menstrual cycle. Thromb Haemostas 55: 388–389
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cortellaro, M., Nencioni, T., Boschetti, C. et al. Cyclic hormonal replacement therapy after the menopause: Transdermal versus oral treatment. Eur J Clin Pharmacol 41, 555–559 (1991). https://doi.org/10.1007/BF00314984
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00314984